RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022

19 9 2022 08:00:01 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering

14 9 2022 22:20:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering

14 9 2022 16:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

07 9 2022 16:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Granted Marketing Authorization by European Commission for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

06 9 2022 16:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Investor Conferences in September

01 9 2022 08:00:01 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 8 2022 16:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Canaccord Genuity 42nd Annual Growth Conference

03 8 2022 08:00:01 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update

02 8 2022 07:00:01 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022

28 7 2022 08:00:02 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼¹ IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome

22 7 2022 08:39:33 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

20 7 2022 08:00:02 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

20 7 2022 08:00:01 提供 Nasdaq GlobeNewswire

NICE Recommends Rhythm’s ▼IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency

18 7 2022 06:00:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity

12 7 2022 07:00:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 7 2022 09:00:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Launches IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency

22 6 2022 08:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces that European Commission Authorized Variation for IMCIVREE® (setmelanotide) to Allow for Dosing in Patients with POMC or LEPR deficiency with Renal Impairment

22 6 2022 08:00:01 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Enters into a Non-dilutive Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 Million

16 6 2022 16:02:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Use in Patients with Bardet-Biedl Syndrome

16 6 2022 16:01:00 提供 Nasdaq GlobeNewswire